DelveInsight’s “Huntington’s Illness Market Insights, Epidemiology, and Market Forecast – 2036” report gives complete insights into the Huntington’s Illness market measurement, historic and forecasted epidemiology, present and rising therapy panorama, and market alternative throughout the 7MM, together with america, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
Obtain DelveInsight’s complete Huntington’s Illness Market Report back to discover rising therapies, key gamers, and future therapy landscapes: https://www.delveinsight.com/report-store/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Key Takeaways from the Huntington’s Illness Market Report
• The worldwide Huntington’s Illness Market was valued at roughly USD 320 million in 2025 and is projected to develop at a CAGR of 14%, pushed by the anticipated entry of disease-modifying gene and RNA-based therapies via 2036.
• In america, the full prevalent instances of Huntington’s Illness stood at roughly 44,000 in 2025, whereas EU4 and the UK collectively recorded roughly 37,000 prevalent instances the identical 12 months.
• Huntington’s Illness is extra prevalent in people aged 60 years and above, accounting for about 50% of complete instances throughout the 7MM.
• AUSTEDO (Teva Prescription drugs) captured the best income amongst accredited therapies, accounting for about USD 167 million in 2025.
• In September 2025, Skyhawk Therapeutics introduced optimistic outcomes from the primary interim evaluation of the Half C affected person cohort in its Part I trial of SKY-0515, exhibiting dose-dependent reductions of mutant huntingtin (mHTT) protein, together with a 62% discount on the 9 mg dose.
• In March 2025, PTC Therapeutics introduced that its Part II PIVOT-HD research of PTC518 (votoplam) met its main endpoint of discount in blood Huntingtin protein ranges at Week 12, with favorable security and tolerability.
• In December 2024, Novartis entered into a world license and collaboration settlement with PTC Therapeutics for PTC518, positioning it as a possible first oral disease-modifying remedy for Huntington’s Illness.
• Main Huntington’s Illness corporations growing therapies embody Teva Prescription drugs, Neurocrine Biosciences, Novartis Prescription drugs, Skyhawk Therapeutics, Alnylam Prescription drugs, Roche, UniQure Biopharma, and others.
Entry DelveInsight’s in-depth Huntington’s Illness Market Evaluation for a better have a look at promising breakthroughs: https://www.delveinsight.com/report-store/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Huntington’s Illness Market Report Scope
The Huntington’s Illness Market Report gives an evaluation of present therapy practices, rising medicine, market share of particular person therapies, and present and forecasted 7MM market measurement from 2022 to 2036. The report additionally covers therapy algorithms, market practices, unmet wants, and key alternatives shaping the longer term market panorama.
Huntington’s Illness Overview
Huntington’s Illness is a uncommon, inherited, progressive mind dysfunction attributable to a mutation within the HTT gene on chromosome 4, ensuing within the manufacturing of irregular huntingtin protein and gradual nerve cell harm. It follows an autosomal dominant inheritance sample, that means people who inherit the defective gene will develop the illness. Signs sometimes emerge in maturity and embody involuntary actions (chorea), cognitive decline, and psychiatric manifestations similar to melancholy and irritability.
Regardless of advances in understanding illness pathology, therapy stays largely symptomatic, with no healing or disease-modifying choices at the moment accessible. Rising concentrate on genetic and biomarker-driven approaches, together with mutant huntingtin (mHTT)-lowering methods, is shaping the longer term therapy paradigm and enabling earlier intervention via gene therapies, antisense oligonucleotides, and RNA-based approaches.
Huntington’s Illness Rising Medicine Profile
SKY-0515 – Skyhawk Therapeutics
SKY-0515 is an orally administered, investigational small molecule RNA modulator developed via Skyhawk’s proprietary SKYSTAR platform. It’s designed to therapeutically scale back each HTT protein and PMS1 protein, the latter being an extra key driver of somatic CAG repeat enlargement and Huntington’s Illness pathology. The Part II/III FALCON-HD trial has expanded worldwide, with greater than 90 sufferers handled so far. This system is at the moment in Part III growth.
Votoplam (PTC518) – Novartis Prescription drugs
Votoplam is a small molecule splicing modifier that acts by way of a novel mechanism to advertise inclusion of a novel pseudoexon containing a untimely termination codon, triggering Huntingtin (HTT) mRNA degradation and subsequent discount in HTT protein ranges. The remedy is licensed to Novartis below a world collaboration with PTC Therapeutics and is at the moment in Part III growth.
Discover groundbreaking therapies and scientific trials within the Huntington’s Illness Market. Entry DelveInsight’s detailed report: https://www.delveinsight.com/report-store/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
The Huntington’s Illness Market Report Gives Insights Into
• Detailed evaluation of corporations growing therapies for Huntington’s Illness, together with market measurement and share estimates by remedy.
• Analysis of therapeutic candidates throughout Part III and Part I levels of growth.
• Evaluation of focused therapeutics, together with RNA modulators, splicing modifiers, and VMAT2 inhibitors.
• Evaluation of pipeline medicine primarily based on growth stage, route of administration, mechanism of motion, and molecule kind.
• Detailed evaluation of collaborations, acquisitions and mergers, licensing agreements, and patent info shaping future market development.
• Complete analysis of marketed and rising therapies and their potential market uptake.
Huntington’s Illness Corporations
Key corporations concerned within the Huntington’s Illness Market embody:
• Teva Prescription drugs
• Neurocrine Biosciences
• Novartis Prescription drugs
• Skyhawk Therapeutics
• Alnylam Prescription drugs
• Roche
• UniQure Biopharma
• Others
Huntington’s Illness Market – Route of Administration
The Huntington’s Illness Market Report gives a therapeutic evaluation of pipeline and marketed medicine by route of administration.
• Oral
Huntington’s Illness Market – Molecule Sorts
Huntington’s Illness merchandise are categorized into the next molecule sorts:
• Small Molecule (VMAT2 Inhibitor)
• RNA Modulator
• RNA Splicing Modifier
• Antisense Oligonucleotide
Obtain DelveInsight’s newest report to realize strategic insights into upcoming therapies and key developments: https://www.delveinsight.com/report-store/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Scope of the Huntington’s Illness Market Report
• Protection: 7MM – United States, EU4, United Kingdom, and Japan
• Research Interval: 2022-2036
• Forecast Interval: 2026-2036
• Huntington’s Illness Corporations: Teva Prescription drugs, Neurocrine Biosciences, Novartis Prescription drugs, Skyhawk Therapeutics, Alnylam Prescription drugs, Roche, UniQure Biopharma, and others
• Huntington’s Illness Therapies: AUSTEDO, INGREZZA, SKY-0515, Votoplam (PTC518), Pridopidine, ANX005, and others
• Huntington’s Illness Market CAGR: Roughly 14% throughout 2026-2036
• Therapeutic Evaluation by Scientific Stage: Marketed, Part III, and Part I
Desk of Contents
• Introduction
• Government Abstract
• Huntington’s Illness: Overview
• Epidemiology and Affected person Burden Evaluation
• Huntington’s Illness Present Remedy Practices
• Huntington’s Illness Marketed Medicine
• Huntington’s Illness Rising Medicine
• Huntington’s Illness Pipeline Growth Actions
• Huntington’s Illness Market Outlook and Medicine Uptake
• Huntington’s Illness Market Entry and Reimbursement
• Newest KOL Views on Huntington’s Illness
• Huntington’s Illness Qualitative Evaluation
• Huntington’s Illness Market Measurement and Forecast, 2022-2036
• Huntington’s Illness Key Corporations
• Huntington’s Illness Market Drivers and Obstacles
• Appendix
Contact Data
Firm Title: DelveInsight Enterprise Analysis LLP
Contact Particular person: Mehul Malhotra
E mail: mmalhotra@delveinsight.com
Handle: 304 S. Jones Blvd #2432
Metropolis: Las Vegas
State: NV
Nation: United States
About DelveInsight
DelveInsight is a number one healthcare-focused market analysis and consulting agency offering high-quality market intelligence and evaluation to help knowledgeable enterprise selections. With a group of skilled business specialists and a deep understanding of the life sciences and healthcare sectors, DelveInsight affords custom-made analysis options and actionable insights to shoppers worldwide.
This launch was printed on openPR.
